The third dose

Phase 1Biologic

BBioSyngen Pte Ltd

The third dose is one of 11 biologic programs targeting Gastrointestinal Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal TumorsRecruiting

Gastrointestinal TumorsPhase 1

Recruiting

Competition

Competitive Landscape

12 competitors in Gastrointestinal Tumors

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Phase 2

1 2

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 3

BL-M24D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 4

BL-M02D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 5

GNC-077

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 6

BL-M09D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 7

BL-M08D1

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 8

Bl-Arc002

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 9

Lutetium BL-ARC001

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 10

The third dose

BBioSyngen Pte Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Gastrointestinal Tumors

NCT06152757

Clinical

Trials by Indication[1]

Gastrointestinal Tumors1 trial

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Recruiting·BBioSyngen Pte Ltd·Phase 1·NCT06152757·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for The third dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — The third dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for The third dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioSyngen Pte Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBioSyngen Pte Ltd

The third dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Gastrointestinal Tumors1 trial

References

Drug Info

Quick Facts

Related News